I

InDex Pharmaceuticals Holding AB
STO:FLERIE

Watchlist Manager
InDex Pharmaceuticals Holding AB
STO:FLERIE
Watchlist
Price: 46.415 SEK 0.51%
Market Cap: 3.6B SEK
Have any thoughts about
InDex Pharmaceuticals Holding AB?
Write Note

InDex Pharmaceuticals Holding AB
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

InDex Pharmaceuticals Holding AB
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Revenue
kr100k
CAGR 3-Years
192%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Revenue
kr1.6B
CAGR 3-Years
1 488%
CAGR 5-Years
63%
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Revenue
kr1.7B
CAGR 3-Years
48%
CAGR 5-Years
85%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Revenue
kr2.5B
CAGR 3-Years
75%
CAGR 5-Years
85%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Revenue
kr5.7m
CAGR 3-Years
N/A
CAGR 5-Years
216%
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Revenue
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

InDex Pharmaceuticals Holding AB
Glance View

Market Cap
3.6B SEK
Industry
Pharmaceuticals

InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

FLERIE Intrinsic Value
5.853 SEK
Overvaluation 87%
Intrinsic Value
Price
I

See Also

What is InDex Pharmaceuticals Holding AB's Revenue?
Revenue
100k SEK

Based on the financial report for Sep 30, 2024, InDex Pharmaceuticals Holding AB's Revenue amounts to 100k SEK.

What is InDex Pharmaceuticals Holding AB's Revenue growth rate?
Revenue CAGR 5Y
-2%

Over the last year, the Revenue growth was -100%. The average annual Revenue growth rates for InDex Pharmaceuticals Holding AB have been 192% over the past three years , -2% over the past five years .

Back to Top